Growth Opportunities in Biologics Contract Development and Manufacturing Organizations, 2024 2029
Growth Opportunities in Biologics Contract Development and Manufacturing Organizations, 2024 2029
Risk-sharing Business Models for Next-generation Biologics Will Drive Bio-CDMO Growth and Spur Future Potential
25-Jun-2024
Global
Market Research
Description
By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more complex treatment modalities, including cell and gene therapy (CGT), nucleic acid therapy, ADC, and bispecific antibodies. Biopharmaceutical companies that focus on these treatments will strive for reduced durations for clinical development and a greater focus on cost-effectively producing drugs with lower costs of goods sold (COGS). Biologics contract development and manufacturing organizations (Bio-CDMOs) are actively framing manufacturing and supply chain strategies, with a specific emphasis on partnering with service providers to optimize the production process.
The US Inflation Reduction Act (IRA) and the BIOSECURE Act have the potential to slow down drug innovation and the demand for CDMO services, leading to radical transformations in global outsourcing dynamics and CDMO strategies. Venture capitalists are assisting their pharmaceutical portfolios by internally restructuring and extending their cash reserves. CDMOs have experienced a consistent decrease in demand, especially for the initial phases of development. However, in late 2023 and 2024, there was a rise in M&A transactions, favorable conditions for biotech financing and valuation, and a stabilization of inflation and interest rates. Demand will resurge, particularly from emerging biopharma and early-stage development, by 2024.
This Frost & Sullivan analysis provides detailed revenue forecasts for the global market of bio-CDMOs. The forecasts are categorized by market and segment, offering valuable insights into the industry. The analysis focuses on highlighting the potential growth opportunities for participants by considering trends, business models, and innovative strategies. The market segments cover various aspects, such as product type, cell expression type, modality, and geographic region. Considering the end of the COVID-19 pandemic and the current global geopolitical issues, demand for outsourcing has decelerated. CDMOs are experiencing a decline in demand, particularly from small and emerging biopharmaceutical companies and those in the early stages of development. This analysis provides a comprehensive examination of future trends, covering the period between 2024 and 2029. It includes insights on capacity expansions, mergers, acquisitions, and the expansion of service offerings. The analysis also investigates the impact of strategic imperatives, growth drivers, restraints, revenue share estimates, and opportunities for bio-CDMOs.
Author: Surbhi Gupta
Table of Contents
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Bio-CDMO Industry
Biologics Industry—Outlook
Biologics Industry—Key Therapeutic Area Outlook
Biologics Pipeline by Modality and Phase
Biologics Industry—Market size and Growth Rate Forecast by Modality
Global Trends Impacting the Bio-CDMO Industry
Global Trends Impacting the Bio-CDMO Industry (continued)
Industry Trends Impacting the Bio-CDMO Industry
Industry Trends Impacting the Bio-CDMO Industry (continued)
Business Model—Shift from Fee-for-service to Value-based Risk-sharing
Value-based Risk-sharing Business Model
Scope of Analysis
Segmentation
Segmentation
Competitive Environment
Key Competitors
Growth Metrics
Growth Drivers
Growth Restraints
Forecast Considerations
Forecast Framework—Bio-CDMO Market Sizing
Forecast Methodology—Bio-CDMO Market
Revenue Forecast
Revenue Forecast by Product Type
Revenue Forecast by Cell-culture Type
Revenue Forecast by Region
Revenue Forecast by Modality
Revenue Forecast Analysis
Revenue Forecast Analysis by Region
Revenue Forecast Analysis by Region (continued)
Revenue Share
Revenue Share Analysis
Growth Metrics
Revenue Forecast
Forecast Analysis
Growth Metrics
Revenue Forecast
Forecast Analysis
Growth Metrics
Revenue Forecast
Forecast Analysis
Growth Metrics
Revenue Forecast
Forecast Analysis
Growth Opportunity 1—Expanding Drug Product Capabilites to Support Anti-obesity Drugs
Growth Opportunity 1—Expanding Drug Product Capabilites to Support Anti-obesity Drugs (continued)
Growth Opportunity 2—Providing End-to-end mRNA Services
Growth Opportunity 2—Providing End-to-end mRNA Services (continued)
Growth Opportunity 3—Indian Domestic Players Enhance Biologics Capabilities
Growth Opportunity 3—Indian Domestic Players Enhance Biologics Capabilities (continued)
Best Practice Recognition
Frost Radar
Benefits and Impacts of Growth Opportunities
Next Steps
Take the Next Step
List of Exhibits
List of Exhibits (continued)
Legal Disclaimer
Growth dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Popular Topics
Deliverable Type | Market Research |
---|---|
Author | Surbhi Gupta |
Industries | Healthcare |
No Index | No |
Is Prebook | No |
Keyword 1 | Biologics contract development |
Keyword 2 | Biologics industry advancements |
Keyword 3 | Biologics CDMO |
Podcast | No |
Predecessor | PDEF-01-00-00-00 |
WIP Number | PFKF-01-00-00-00 |